2seventy bio (TSVT) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free TSVT Stock Alerts $4.19 -0.10 (-2.33%) (As of 12:46 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadline2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Whymsn.com - April 17 at 1:11 PM2seventy bio Inc Ordinary Sharesmorningstar.com - April 13 at 9:15 AMCiti raises 2Seventy Bio stock target on FDA approvalinvesting.com - April 10 at 11:37 PMAnalysts Offer Predictions for 2seventy bio, Inc.'s Q1 2024 Earnings (NASDAQ:TSVT)marketbeat.com - April 10 at 8:12 AMLeerink Partnrs Analysts Raise Earnings Estimates for 2seventy bio, Inc. (NASDAQ:TSVT)marketbeat.com - April 9 at 6:25 AMPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamicsmarkets.businessinsider.com - April 8 at 7:36 PM2seventy bio (NASDAQ:TSVT) Price Target Raised to $12.00marketbeat.com - April 8 at 7:29 PMBuy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlookmarkets.businessinsider.com - April 7 at 7:49 PMBristol Myers Wins FDA Nod for Abecmamsn.com - April 5 at 4:27 PMFDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancermsn.com - April 5 at 4:27 PMBristol Myers, 2seventy bio's Abecma approved for earlier line multiple myelomaseekingalpha.com - April 5 at 4:27 PMU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapyfinance.yahoo.com - April 5 at 9:35 AM2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Hold" from Brokeragesmarketbeat.com - April 4 at 2:15 AMInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of Stockinsidertrades.com - March 26 at 4:18 AMInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Acquires 300,000 Shares of Stockmarketbeat.com - March 25 at 11:49 PM2seventy bio appoints Eli Casdin and Charles Newton to its board of directorsmsn.com - March 20 at 6:07 PM2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directorsbusinesswire.com - March 20 at 5:04 PMThinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?morningstar.com - March 20 at 1:07 PM2seventy bio (NASDAQ:TSVT) Given "Neutral" Rating at Wedbushmarketbeat.com - March 18 at 2:52 PMBristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approvalmarketwatch.com - March 17 at 10:41 AMBristol Myers wins FDA AdCom backing for Abecma label expansionmsn.com - March 16 at 8:41 AMAnalysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)markets.businessinsider.com - March 15 at 3:40 PMmarketbeat.com - March 15 at 1:10 PM2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapymarketwatch.com - March 14 at 9:47 AMQ1 2024 EPS Estimates for 2seventy bio, Inc. Decreased by Wedbush (NASDAQ:TSVT)marketbeat.com - March 8 at 6:18 AM2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 7 at 6:21 PM2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call Transcriptmsn.com - March 7 at 1:21 PMBuy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial Outlookmarkets.businessinsider.com - March 7 at 7:49 AMDowngrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Termfinance.yahoo.com - March 7 at 7:49 AMWhen Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?finance.yahoo.com - March 6 at 4:47 PM2seventy bio (NASDAQ:TSVT) Announces Earnings Resultsmarketbeat.com - March 6 at 9:45 AMTSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 5 at 8:37 AM2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progressfinance.yahoo.com - March 5 at 7:39 AMA Preview Of 2seventy bio's Earningsbenzinga.com - March 4 at 3:17 PM2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferencesbusinesswire.com - March 1 at 7:00 AM2seventy bio (TSVT) Price Target Increased by 33.33% to 10.88msn.com - February 24 at 10:10 PMTSVT Mar 2024 2.500 putfinance.yahoo.com - February 18 at 1:58 PM2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Rating of "Hold" by Brokeragesmarketbeat.com - February 14 at 1:38 AMTSVT Jun 2024 5.000 putca.finance.yahoo.com - February 9 at 6:48 PMBristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODACfinance.yahoo.com - February 6 at 12:27 PM2seventy bio and BMS Schedule FDA Panel for Abecmamsn.com - February 6 at 7:26 AMBristol Myers, 2seventy bio to face FDA panel in March for Abecma decisionmsn.com - February 5 at 8:00 AMBuy Rating Affirmed for 2seventy bio Amidst Revenue Stabilization and Strategic Growth Initiativesmarkets.businessinsider.com - February 3 at 5:54 PM2seventy bio, Inc. Forecasted to Earn FY2023 Earnings of ($4.30) Per Share (NASDAQ:TSVT)marketbeat.com - February 2 at 7:40 AMLeerink ups 2seventy to outperform, cites attractiveness as takeover targetmsn.com - February 1 at 8:26 AMLeerink Partnrs Comments on 2seventy bio, Inc.'s Q1 2025 Earnings (NASDAQ:TSVT)marketbeat.com - February 1 at 6:45 AM2seventy bio (NASDAQ:TSVT) Rating Increased to Outperform at Leerink Partnrsmarketbeat.com - February 1 at 6:00 AM2seventy bio Divests Programs to Regeneron Pharmaceuticalsmsn.com - February 1 at 1:16 AMTD Cowen Reiterates Market Perform Rating for 2seventy bio (NASDAQ:TSVT)marketbeat.com - January 31 at 8:21 AM2seventy bio (NASDAQ:TSVT) Rating Increased to Outperform at SVB Leerinkmarketbeat.com - January 31 at 7:36 AM Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 TSVT Media Mentions By Week TSVT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSVT News Sentiment▼1.000.33▲Average Medical News Sentiment TSVT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSVT Articles This Week▼02▲TSVT Articles Average Week Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Telomir Pharmaceuticals News Today Xeris Biopharma News Today Puma Biotechnology News Today AC Immune News Today Foghorn Therapeutics News Today Werewolf Therapeutics News Today Nanobiotix News Today AEON Biopharma News Today Vanda Pharmaceuticals News Today Prelude Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSVT) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
